Steven M. Horwitz

19.7k citations

239 papers · 7.0k indexed · 2 hit papers · h-index 42

Pathology and Forensic Medicine top 0.05%
Oncology top 0.5%
Immunology top 1%
Dermatology top 0.2%
Genetics top 0.5%

Co-authors: Alison J. Moskowitz Mark W. Clemens Owen A. O’Connor Andrew D. Zelenetz Craig H. Moskowitz Eric D. Jacobsen Carol S. Portlock Paul A. Hamlin
Topics: Lymphoma Diagnosis and Treatment (160 papers)T-cell and Retrovirus Studies (73 papers)Chronic Lymphocytic Leukemia Research (57 papers)
Cited by: Pathology and Forensic Medicine Dermatology Genetics
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
Partner nations: United States Italy United Kingdom

In The Last Decade

Steven M. Horwitz

226 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Steven M. Horwitz

Since Specialization

Citations

This map shows the geographic impact of Steven M. Horwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven M. Horwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven M. Horwitz more than expected).

Fields of papers citing papers by Steven M. Horwitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven M. Horwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven M. Horwitz. The network helps show where Steven M. Horwitz may publish in the future.

Co-authorship network of co-authors of Steven M. Horwitz

This figure shows the co-authorship network connecting the top 25 collaborators of Steven M. Horwitz. A scholar is included among the top collaborators of Steven M. Horwitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven M. Horwitz. Steven M. Horwitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New treatments for adult T-cell leukemia/lymphoma 2025 ·Leukemia Research ·Zachary D. Epstein‐Peterson,(unknown),Steven M. Horwitz	2
2	Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP 2024 ·Blood Advances ·(unknown),Alexandra N. Smith,Matthew J. Maurer,Julie Teruya‐Feldstein,Matthew J. Matasar,Alison J. Moskowitz,David J. Straus,Ariela Noy,M. Lia Palomba,Steven M. Horwitz,Paul A. Hamlin,Carol S. Portlock,James R. Cerhan,Thomas M. Habermann,Gilles Salles,Grzegorz S. Nowakowski,Craig H. Moskowitz,Andrew D. Zelenetz	2
3	CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas 2024 ·PubMed ·Paola Ghione,(unknown),Erel Joffe,M. Lia Palomba,Ariela Noy,Philip Caron,Paul A. Hamlin,Anita Kumar,Matthew J. Matasar,Colette Owens,Alison J. Moskowitz,Lorenzo Falchi,David J. Straus,Steven M. Horwitz,Gilles Salles,Ahmet Doǧan,Andrew D. Zelenetz	1
4	Current Treatment of Peripheral T-cell Lymphoma 2022 ·PubMed ·Steven M. Horwitz	6
5	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project 2021 ·Blood ·Ranjana H. Advani,Tetiana Skrypets,Monica Civallero,Michael A. Spinner,Martina Manni,Won-Seog Kim,Andrei R. Shustov,Steven M. Horwitz,Felicitas Hitz,María Elena Cabrera,Iván Dlouhy,José Vassallo,Stefano Pileri,Giorgio Inghirami,Silvia Montoto,Umberto Vitolo,John Radford,Julie M. Vose,Massimo Federico	60
6	Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) 2019 ·Blood ·Ahmed Sawas,Helen Ma,Andrei R. Shustov,(unknown),Gajanan Bhat,Mark Acosta,Steven M. Horwitz,Owen A. O’Connor	5
7	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma 2019 ·Blood ·Sven Borchmann,Erel Joffe,Craig H. Moskowitz,Andrew D. Zelenetz,Ariela Noy,Carol S. Portlock,John F. Gerecitano,Connie Lee Batlevi,Philip Caron,Pamela Drullinsky,Audrey Hamilton,Paul A. Hamlin,Steven M. Horwitz,Anita Kumar,Matthew J. Matasar,Alison J. Moskowitz,Colette Owens,M. Lia Palomba,Anas Younes,David J. Straus	26
8	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 2019 ·American Journal of Hematology ·Francine M. Foss,Steven M. Horwitz,Monica Civallero,Monica Bellei,Luigi Marcheselli,Won Seog Kim,María Elena Cabrera,Iván Dlouhy,Arnon Nagler,Ranjana H. Advani,Emanuela Anna Pesce,Young Hyeh Ko,Silvia Montoto,Carlos Chiattone,Alison J. Moskowitz,Michele Spina,Marina Cesaretti,Irène Biasoli,Massimo Federico	38
9	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse 2019 ·Blood Cancer Journal ·Anita Kumar,Fushen Sha,Ahmed Toure,Ahmet Doǧan,Ai Ni,Connie Lee Batlevi,Maria Lia Palomba,Carol S. Portlock,David J. Straus,Ariela Noy,Steven M. Horwitz,Alison J. Moskowitz,Paul A. Hamlin,Craig H. Moskowitz,Matthew J. Matasar,Andrew D. Zelenetz,Anas Younes	76
10	Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma 2018 ·Blood ·Graham P. Collins,Steven M. Horwitz,Andrew Davies,Anand B. Karnad,Felipe Samaniego,Alexander I. Spira,Paul Fields,Tobias Menne,Joseph Boni,Hans G. Cruz,Jay Feingold,Shui He,Jens Wuerthner,Mehdi Hamadani	17
11	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma 2018 ·Blood ·Mehdi Hamadani,Graham P. Collins,Felipe Samaniego,Alexander I. Spira,Andrew Davies,John Radford,Paolo Caimi,Tobias Menne,Joseph Boni,Hans G. Cruz,Jay Feingold,Shui He,Jens Wuerthner,Steven M. Horwitz	35
12	Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies 2017 ·Blood ·Ian W. Flinn,Susan O’Brien,Brad S. Kahl,Manish R. Patel,Yasuhiro Oki,(unknown),Pierluigi Porcu,Jeffrey A. Jones,Jan A. Burger,Nitin Jain,Virginia Kelly,Kerstin Allen,Mark Douglas,Jennifer Sweeney,Patrick Kelly,Steven M. Horwitz	183
13	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Studybreakdown → 2015 ·Journal of Clinical Oncology ·Owen A. O’Connor,Steven M. Horwitz,Tamás Masszi,Achiel Van Hoof,Peter de Nully Brown,Jeanette K. Doorduijn,Georg Heß,Wojciech Jurczak,Poul Knoblauch,Shanta Chawla,Gajanan Bhat,Mi Rim Choi,Jan Walewski,Kerry J. Savage,Francine M. Foss,Lee F. Allen,Andrei R. Shustov	386
14	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( PTCL ): final results from the T‐ cell consortium trial 2015 ·British Journal of Haematology ·Ranjana H. Advani,Stephen M. Ansell,Mary Jo Lechowicz,Anne Beaven,Fausto R. Loberiza,Kenneth R. Carson,Andrew M. Evens,Francine M. Foss,Steven M. Horwitz,Barbara Pro,Lauren Pinter‐Brown,Sonali M. Smith,Andrei R. Shustov,Kerry J. Savage,Julie M. Vose	66
15	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108 2015 ·Journal of Clinical Oncology ·Paul M. Barr,Hongli Li,Catherine Spier,Daruka Mahadevan,Michael LeBlanc,Mansoor Ul Haq,(unknown),Christopher R. Flowers,Nina D. Wagner‐Johnston,Steven M. Horwitz,Richard I. Fisher,Bruce D. Cheson,Sonali M. Smith,Brad S. Kahl,Nancy L. Bartlett,Jonathan W. Friedberg	91
16	How I treat the peripheral T-cell lymphomas 2014 ·Blood ·Alison J. Moskowitz,Matthew A. Lunning,Steven M. Horwitz	99
17	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Studybreakdown → 2011 ·Journal of Clinical Oncology ·Owen A. O’Connor,Barbara Pro,Lauren Pinter‐Brown,Nancy L. Bartlett,Leslie Popplewell,Bertrand Coiffier,Mary Jo Lechowicz,Kerry J. Savage,Andrei R. Shustov,Christian Gisselbrecht,Eric D. Jacobsen,Pier Luigi Zinzani,Richard R. Furman,André Goy,Corinne Haïoun,Michael Crump,Jasmine Zain,Eric D. Hsi,Adam P. Boyd,Steven M. Horwitz	439
18	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma 2010 ·Journal of Clinical Oncology ·Craig H. Moskowitz,Heiko Schöder,Julie Teruya‐Feldstein,Camelia S. Sima,Alexia Iasonos,Carol S. Portlock,David J. Straus,Ariela Noy,Maria Lia Palomba,Owen A. O’Connor,Steven M. Horwitz,Sarah A. Weaver,(unknown),Daniel A. Filippa,James F. Caravelli,Paul A. Hamlin,Andrew D. Zelenetz	225
19	Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies 2009 ·Journal of Clinical Oncology ·Owen A. O’Connor,Steven M. Horwitz,Paul A. Hamlin,Carol S. Portlock,Craig H. Moskowitz,Debra Sarasohn,Ellen Neylon,(unknown),(unknown),Barbara MacGregor‐Cortelli,Molly Bruce Patterson,Venkatraman Seshan,(unknown),Martin Fleisher,Diane R. Mould,M.I. Saunders,Andrew D. Zelenetz	131
20	Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies 2005 ·Journal of Clinical Oncology ·Owen A. O’Connor,Mark Heaney,Lawrence B. Schwartz,(unknown),(unknown),Barbara MacGregor‐Cortelli,(unknown),Craig H. Moskowitz,Carol S. Portlock,Steven M. Horwitz,Andrew D. Zelenetz,Stanley Frankel,Victoria M. Richon,Paul A. Marks,William Kevin Kelly	345

About Steven M. Horwitz

Steven M. Horwitz is a scholar working on Pathology and Forensic Medicine, Genetics and Immunology, having authored 239 papers that have together received 7.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (160 papers), T-cell and Retrovirus Studies (73 papers) and Chronic Lymphocytic Leukemia Research (57 papers). The work is most often cited by research in Pathology and Forensic Medicine (4.8k citations), Dermatology (1.5k citations) and Genetics (1.3k citations). Steven M. Horwitz has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Alison J. Moskowitz, Mark W. Clemens, Owen A. O’Connor, Andrew D. Zelenetz, Craig H. Moskowitz, Eric D. Jacobsen, Carol S. Portlock, Paul A. Hamlin, Nancy L. Bartlett and Matthew A. Lunning. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact